Cygnus gains development grants for GlucoWatch:
This article was originally published in Clinica
Executive Summary
Cygnus has received two grants worth a total of $200,000 from the US National Institutes of Health to support the development of its noninvasive, automatic glucose monitoring system, the GlucoWatch Biographer. The first grant will be used to develop a method for predicting hypoglycaemic events, while the second will focus on using a predictive kinetic method to reduce the effects of certain variables on results obtained with the Biographer. The FDA granted Redwood City, California-based Cygnus an approvable letter for its GlucoWatch in May.
You may also be interested in...
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.
Report Finds Digital Diabetes Tools Deliver No ‘Meaningful Clinical Benefits'
A new report from health economics group the Peterson Health Technology Institute found that apps to help patients manage their blood sugar levels delivered few of the promised benefits. However, a digital therapeutics industry association says PHTI’s research cast too narrow a net.
Merck’s Winrevair Well Positioned To Benefit From Medicare Part D Redesign
Significant cost sharing reductions under the redesign will enhance uptake of the pulmonary arterial hypertension drug. The trade-off is a 20% mandatory price discount in the catastrophic phase.